Abstracts

RISK FACTORS FOR NEW HIV INFECTIONS IN THE GENERAL POPULATION IN SUB-SAHARAN AFRICA

Previous work identified risk factors for new HIV infections in sub-Saharan African populations but patterns of association are not consistent across studies.  Different risk factor definitions and low power may explain some inconsistencies. Statistical power has not previously been estimated in these risk factor analyses.  We harmonised population-based longitudinal data from general population studies in…

ADEQUATE DOLUTEGRAVIR EXPOSURE DOSED BID WITH RIFAMPICIN IN CHILDREN 6 TO

Adults with HIV/TB co-infection on dolutegravir (DTG)-based antiretroviral therapy (ART) can overcome the induction effect of rifampicin (RIF) by doubling the DTG dose (50mg twice(BID) instead of once(QD) daily.  We undertook a pharmacokinetic (PK) substudy nested within the ongoing ODYSSEY randomised controlled trial (#NCT02259127) to evaluate DTG PK in HIV/TB co-infected children while receiving DTG…

MARAVIROC SAFETY & PHARMACOKINETICS IN HIV-EXPOSED NEONATES

Lack of adequate safety and pharmacokinetic (PK) data limits antiretroviral (ARV) prophylaxis and treatment options in HIV-exposed neonates. Maraviroc (MVC), a CCR5 receptor antagonist approved for use in adults, has potential for use in prophylaxis and treatment of HIV-exposed or infected neonates. IMPAACT 2007 is an ongoing Phase I, multi-center, open-label study of MVC safety…